NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free CATX Stock Alerts $1.08 -0.08 (-6.90%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.05▼$1.2950-Day Range N/A52-Week Range$0.21▼$1.91Volume8.61 million shsAverage Volume6.56 million shsMarket Capitalization$672.44 millionP/E RatioN/ADividend YieldN/APrice Target$1.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.9% Upside$1.90 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 14 Articles This WeekInsider TradingAcquiring Shares$317,849 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.11) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.61 out of 5 starsMedical Sector368th out of 915 stocksSurgical & Medical Instruments Industry48th out of 98 stocks 4.5 Analyst's Opinion Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CATX. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 2.5 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Perspective Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows9 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $317,849.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Perspective TherapeuticsPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesJune 14 at 12:40 PM | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 100,000 SharesJune 5, 2024 | insidertrades.comLori A. Woods Buys 34,246 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockJune 4, 2024 | insidertrades.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CFO Purchases 25,006 Shares of StockMay 31, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III Buys 30,031 SharesMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksJune 15 at 5:50 AM | americanbankingnews.comPerspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Royal Bank of CanadaJune 15 at 1:30 AM | americanbankingnews.comPerspective Therapeutics (NYSE:CATX) Shares Gap Up Following Insider Buying ActivityJune 13 at 2:46 AM | americanbankingnews.comPerspective Therapeutics Stock to Reverse Split on Monday, June 17th (NYSE:CATX)June 12 at 7:00 AM | globenewswire.comPerspective Therapeutics Announces Inclusion in the Russell 3000® IndexJune 11, 2024 | globenewswire.comPerspective Therapeutics Announces 1-for-10 Reverse Stock SplitJune 11, 2024 | americanbankingnews.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives $1.90 Average PT from BrokeragesJune 10, 2024 | globenewswire.comPerspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingJune 5, 2024 | americanbankingnews.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Lori A. Woods Buys 34,246 Shares of StockJune 5, 2024 | americanbankingnews.comRobert F. Williamson III Buys 55,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockMay 27, 2024 | seekingalpha.comPerspective Therapeutics: An Elevated Theranostics Play Flying Under Your RadarMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Promising Competitor Data and Treatment InnovationsMay 24, 2024 | globenewswire.comPerspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMay 20, 2024 | globenewswire.comPerspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024May 17, 2024 | bizjournals.comGT Medical Technologies acquires cancer treatment subsidiary from Seattle companyMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)May 15, 2024 | bizjournals.comPerspective Therapeutics sells subsidiary to Arizona companyMay 15, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024May 15, 2024 | washingtonpost.comPerspective Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:CATX CUSIPN/A CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees116Year FoundedN/APrice Target and Rating Average Stock Price Target$1.90 High Stock Price Target$3.00 Low Stock Price Target$1.40 Potential Upside/Downside+75.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-302.70% Pretax Margin-3,379.88% Return on Equity-46.38% Return on Assets-39.17% Debt Debt-to-Equity Ratio0.01 Current Ratio12.98 Quick Ratio12.98 Sales & Book Value Annual Sales$1.43 million Price / Sales470.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.00Miscellaneous Outstanding Shares622,630,000Free Float600,712,000Market Cap$672.44 million OptionableN/A Beta1.42 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsiRhythm TechnologiesNASDAQ:IRTCInari MedicalNASDAQ:NARIICU MedicalNASDAQ:ICUIIntegra LifeSciencesNASDAQ:IARTNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsJohan M SpoorBought 100,000 shares on 6/13/2024Total: $117,000.00 ($1.17/share)Lori A WoodsBought 34,246 shares on 6/3/2024Total: $49,999.16 ($1.46/share)Robert F Williamson IIIBought 55,000 shares on 5/31/2024Total: $75,900.00 ($1.38/share)Jonathan Robert HuntBought 25,006 shares on 5/31/2024Total: $35,008.40 ($1.40/share)Robert F Williamson IIIBought 30,031 shares on 5/29/2024Total: $39,941.23 ($1.33/share)View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions Should I buy or sell Perspective Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CATX shares. View CATX analyst ratings or view top-rated stocks. What is Perspective Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued 1-year price targets for Perspective Therapeutics' shares. Their CATX share price targets range from $1.40 to $3.00. On average, they expect the company's share price to reach $1.90 in the next year. This suggests a possible upside of 75.9% from the stock's current price. View analysts price targets for CATX or view top-rated stocks among Wall Street analysts. How have CATX shares performed in 2024? Perspective Therapeutics' stock was trading at $1.19 at the beginning of 2024. Since then, CATX shares have decreased by 9.2% and is now trading at $1.08. View the best growth stocks for 2024 here. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The business earned $0.33 million during the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative trailing twelve-month return on equity of 46.38%. When did Perspective Therapeutics' stock split? Shares of Perspective Therapeutics reverse split before market open on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.03%), Janus Henderson Group PLC (2.23%), Affinity Asset Advisors LLC (0.87%), Baker BROS. Advisors LP (0.03%), Virtu Financial LLC (0.02%) and RIA Advisory Group LLC (0.02%). Insiders that own company stock include Johan M Spoor, Jonathan Robert Hunt, Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann and Robert F Williamson III. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CATX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.